{
    "nctId": "NCT01837225",
    "briefTitle": "ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI and Eagle Imaging Devices",
    "officialTitle": "ALA-induced Fluorescence Imaging of Breast Cancers Using the Handheld PRODIGI and Eagle Imaging Devices",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 90,
    "primaryOutcomeMeasure": "The sensitivities and specificities for the two (oral) doses of 5-ALA (15 mg/kg and 30 mg/kg) and control (0 mg/kg ALA) in differentiating cancer/normal tissue.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female patients with breast cancer\n2. 18 years or older\n3. Have consented for their standard surgeries for primary invasive breast cancers, with or without auxiliary procedure.\n4. Have existing biopsies banked at the hospital (for ALA patients)\n\nExclusion Criteria:\n\n1. Pre-operative therapy (including chemotherapy, endocrine therapy and radiotherapy)\n2. Inability to consent\n3. Prior history of photosensitivity, liver disease, or recurrent disease\n4. Pregnancy\n5. Absence of in-house core biopsy in tissue bank",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}